LBLinnea M. Baudhuin

Linnea M. Baudhuin

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Linnea M. Baudhuin has a total of 180 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Beyond the Aorta: Extra-Aortic Vascular Disease and Screening in Heritable and Systemic Arteriopathies

    by Hussein Abdul Nabi, Luke Dreher, Meer Husain, Arshad Mohammed, Anthony Tannous, Mirna Hussein, Brendan Saunders, Jack Hartnett, Mahmoud Abdelnabi, Linnea M. Baudhuin, et al.

    Heritable thoracic aortic disease (HTAD) comprises genetic disorders that predispose to thoracic aortic aneurysm and dissection. Several also affect arteries beyond the aorta. This narrative review examines the burden, distribution, mechanisms, and screening implications of extra-aortic vascular disease in vascular Ehlers–Danlos syndrome (vEDS), Loeys–Dietz syndrome (LDS), Marfan syndrome (MFS), and nonsyndromic HTAD, alongside the related systemic arteriopathies spontaneous coronary artery dissection (SCAD) and fibromuscular dysplasia (FMD). Disease- and genotype-specific patterns emerge, although estimates differ with referral patterns, imaging coverage, and outcome definitions. In the Montalcino Aortic Consortium (MAC), COL3A1 carriers had the highest proportion of extra-aortic clinical arterial events, with prominent abdominopelvic and cervical involvement. LDS showed widespread arterial disease and head and neck involvement. MFS had fewer clinical arterial events, but imaging studies identified branch aneurysms, particularly in patients with advanced aortic disease. SCAD and FMD frequently involved additional vascular territories. Findings from broader nonsyndromic thoracic aortic disease cohorts should be distinguished from genetically confirmed HTAD. Imaging-detected aneurysm prevalence and clinical event proportions are not interchangeable. Guidelines and consensus support disease-specific vascular assessment, but anatomical coverage, surveillance intervals, and evidence strength vary. Comprehensive baseline imaging is supported in LDS, FMD, and SCAD; European guidance also recommends peripheral surveillance in vEDS and MFS. Additional assessment in nonsyndromic HTAD and cervical artery dissection depends on genotype and clinical features. We outline a practical framework integrating the presenting vascular lesion, molecular diagnosis, prior events, family history, and imaging-related burden, and discuss when an extra-aortic presentation should prompt aortic evaluation. Prospective studies are needed to establish whether increased detection and changes in management improve patient-important outcomes.

  • Open Access

    Prevalence, Predictors, and Clinical Outcomes of Cervical Arterial Dissection in Patients with Spontaneous Coronary Artery Dissection: A Multicenter Retrospective Cohort Study

    by Hend Bcharah, Hussein Abdul Nabi, Luke Dreher, George Bcharah, Katie Mand, Vinicius De Sousa Barzon Serra, Linnea M. Baudhuin, Yuxiang Wang, Mayowa A. Osundiji, Fadi E. Shamoun

    Background: Patients with spontaneous coronary artery dissection (SCAD) are at increased risk of cardiovascular events, including dissection in other arterial territories such as cervical arteries. Those with combined coronary and cervical arterial dissection (CACAD) may have more widespread arterial abnormalities and worse outcomes, underscoring the need for better risk stratification and personalized care. Objective: This study examined the prevalence of cervical artery dissection (CvAD) in patients diagnosed with SCAD, evaluated potential risk factors for developing CvAD, and assessed their impact on clinical outcomes, including all-cause mortality, SCAD recurrence, and stroke. The goal was to enhance risk stratification by identifying SCAD patients at increased risk for CvAD. Design: In this retrospective cohort study, patients diagnosed with SCAD between 2018 and 2024 across Mayo Clinic sites were identified using ICD-10 codes. Manual chart review confirmed CvAD diagnoses. Patients were stratified based on the presence or absence of CvAD. Chi-square and independent t-tests were used to compare risk factors and comorbidities. Univariate screening and multivariable logistic regression were used to identify predictors of CvAD. Results: Among 1380 patients with SCAD, 131 (9.5%) had CvAD. The median follow-up was 2.02 years (IQR: 1.1–5.2 years). All CvAD diagnoses were identified after the index SCAD event through systematic post-SCAD vascular imaging. The mean age was similar between groups (51.5 ± 11.3 years in CACAD vs. 50.9 ± 10.7 years in SCAD-only, p = 0.540), and the majority were female (93.9% vs. 91.9%, p = 0.529). Multivariable regression identified extremity arterial dissection (OR: 8.13, 95% CI: 3.41–19.36, p < 0.001), fibromuscular dysplasia (FMD) (OR: 7.52, 95% CI: 4.67–12.10, p < 0.001), connective tissue disorders (CTDs) (OR: 6.85, 95% CI: 2.35–19.98, p < 0.001), and anxiety (OR: 1.69, 95% CI: 1.01–2.81, p = 0.044) as significant predictors of CvAD. CvAD was a strong independent predictor of stroke (OR: 6.37, 95% CI: 2.93–13.87, p < 0.001). Mortality and SCAD recurrence did not differ significantly between groups. Conclusions: Patients with CACAD demonstrate a systemic vascular phenotype with significantly higher rates of FMD, connective tissue disease, extremity arterial dissection, and stroke. These findings highlight the importance of comprehensive vascular screening and individualized monitoring in at-risk SCAD patients.


  • Open Access

    Pregnancy-Related Vascular Outcomes in Loeys–Dietz Syndrome: A Retrospective Cohort Study and Case Series

    by Amal Youssef, Hend Bcharah, Hussein Abdul Nabi, George Bcharah, Luke Dreher, Mohammed Alaa Raslan, Fares Jamal, Linnea Baudhuin, Mayowa A. Osundiji, Yuxiang Wang, et al.

    Background: Loeys–Dietz syndrome (LDS) is an autosomal dominant aortopathy characterized by aggressive aneurysm formation and arterial dissections. Pregnancy-related outcomes and timing of LDS diagnosis remain poorly characterized. Methods: Demographics, genetic, obstetric, and vascular data was collected from genetically or clinically confirmed individuals with LDS seen at the three Mayo Clinic sites from 2018 to 2025. Aneurysm progression, new aneurysm formation, and arterial dissections were recorded across all vascular beds. Vascular events were assessed during pregnancy, within 12 months postpartum, and during breastfeeding. Comparative analyses were performed between women with and without a history of pregnancy, and a single-arm descriptive analysis was conducted among patients who experienced vascular complications during the peripartum period. Continuous variables were compared using the Mann–Whitney U test, while categorical variables were analyzed using chi-square or Fisher exact tests. Results: Of 47 women with LDS, 24 had a history of pregnancy, accounting for 54 pregnancies. In the comparative analysis, age at LDS diagnosis differed significantly between women with and without a prior pregnancy: women without prior pregnancy were diagnosed at a younger age (median 23.5 years [IQR 10.8–41.0], n = 23) than those who had been pregnant (median 53.5 years [IQR 43.0–59.3], n = 24). Among pregnant women, the median age at first pregnancy was 28 years (IQR 23–34); only 4 (16.7%) knew their diagnosis before pregnancy. Of 54 pregnancies, 40 (74.1%) resulted in live birth, with 23 (57.5%) vaginal and 17 (42.5%) cesarean deliveries; preterm delivery occurred in 1 (2.5%) pregnancy, and postpartum hemorrhage in 2 (5.0%). No maternal deaths, aortic dissections, or uterine ruptures occurred during gestation or the first postpartum year. In addition, 14 women (58.3%) developed aneurysms, 6 (25.0%) experienced at least one arterial dissection, and 7 (29.2%) required surgical repair, predominantly involving the ascending and abdominal aorta. The prevalence of vascular complications did not differ significantly between groups. Conclusions: In this LDS cohort, pregnancy and the early postpartum period were not accompanied by acute aortic catastrophes, despite frequent diagnostic delay. Although women without prior pregnancy were diagnosed at a younger age, the overall burden of vascular and morphologic complications did not differ significantly by pregnancy history. These findings highlight the importance of long-term cardiovascular follow-up in women with LDS.


  • Open Access

    The Role of Genetic Variation in Phenotypic Variability in Loeys–Dietz Syndrome

    by Hussein Abdul Nabi, Luke Dreher, Jack Hartnett, Ashley Crossley, Hussein El Ghandour, Mayowa Osundiji, Hicham El Masry, Chadi Ayoub, Fadi E. Shamoun, Linnea M. Baudhuin

    Background: Loeys–Dietz syndrome (LDS) is a heritable connective tissue disorder caused by pathogenic variants in genes of the transforming growth factor‐ β (TGF‐ β ) signaling pathway. Although genotype–phenotype correlations have been suggested, comprehensive comparative data across LDS subtypes remain limited. Improved understanding of these correlations is essential to guide individualized surveillance and management strategies. Methods: We conducted a retrospective cohort study of adults with genetically confirmed LDS evaluated between 2018 and 2024 across Mayo Clinic sites. Patients with pathogenic, likely pathogenic, or suspicious variants in TGFBR1 , TGFBR2 , or SMAD3 were included. Clinical characteristics, physical examination findings, cardiovascular and noncardiovascular manifestations, surgical interventions, and mortality were compared across genotypes. Categorical variables were analyzed using chi‐square tests and continuous variables using parametric or nonparametric methods as appropriate. Results: A total of 93 patients were included (29 TGFBR1 , 33 TGFBR2 , 31 SMAD3 ). Demographics and mortality did not differ significantly between groups. Patients with TGFBR1 and TGFBR2 demonstrated trends toward higher rates of ascending aortic aneurysm and aortic dissection compared with SMAD3 patients, though these differences were not statistically significant. Renal artery aneurysms were significantly more common in TGFBR1 patients (13.8%, p = 0.010). SMAD3 patients had significantly higher rates of mitral regurgitation (54.8%, p = 0.04), peripheral neuropathy (29.0%, p = 0.018), and trends toward increased atrial fibrillation and osteoarthritis. A novel association was identified between TGFBR1 variants and migraine, which was significantly more prevalent in this group (62.1%, p = 0.017). The rates of major cardiovascular surgical interventions were high and comparable across all genotypes. Conclusion: Distinct genotype–phenotype associations exist among LDS subtypes. TGFBR1 and TGFBR2 variants are associated with a greater burden of aggressive vascular disease, whereas SMAD3 variants are linked to mitral valve disease, peripheral neuropathy, and osteoarthritis. We also identified a novel association between TGFBR1 genotype and migraine. These findings reinforce the importance of comprehensive genetic testing to inform personalized surveillance and management strategies in LDS.

  • Open Access

    Autosomal-Recessive LMNA Dilated Cardiomyopathy

    by Rosalie M. Sterner, Lea M. Coon, John L. Black, Ann M. Moyer, Joseph J. Maleszewski, Linnea M. Baudhuin


  • Exome Sequencing Enhances Screening for Familial Hypercholesterolemia Within a Multi-Site Healthcare System

    by N. Jewel Samadder, Mariah Schroeder, Molly M. Voss, Fadi Shamoun, Iftikhar Kullo, Timothy B. Curry, Elisa J.F. Houwink, Michelle L. Bublitz, Lorelei A. Bandel, Sebastian M. Armasu, et al.

    BACKGROUND: Familial hypercholesterolemia (FH) is an autosomal dominant genetic disorder that increases risk for premature coronary artery disease and has accessible and effective interventions. The Dutch lipid clinic network is currently the most used diagnostic criterion; however, genetic sequencing provides a definitive diagnosis of FH. The goals of this study were to determine whether germline genetic screening using exome sequencing could be used to efficiently identify individuals who were genotype positive for FH. METHODS: Participants were recruited from 3 geographically and racially diverse sites in the United States (Rochester, MN; Phoenix, AZ; and Jacksonville, FL). Participants underwent Exome+ sequencing (dba Helix, San Mateo, CA) and return of results for specific genetic findings in APOB , LDLR , or PCSK9 . A chart review was performed to collect demographics, personal, and family cardiovascular history. RESULTS: At the time of the study, 84 413 participants were enrolled in the Tapestry study. Annotation and interpretation of all variants in genes for FH resulted in the identification of 419 likely pathogenic and pathogenic variants (prevalence, 0.50%), which included 116 APOB , 298 LDLR , and 5 PCSK9 . Sixty-six percent were female, the mean body mass index was 27.3, with 12.3% reporting a history of diabetes. Hypertriglyceridemia (≥150 mg/dL) was present in 39.5% and reduced HDL (<50 mg/dL) was present in 56.7% of patients. 27.5% of patients were not on cholesterol-lowering medications, and only 10% of FH carriers were at goal low-density lipoprotein cholesterol levels. A history of coronary artery disease was reported in 22.4% of the cohort. Nearly 90% of these participants were newly diagnosed carriers of FH. Only 30.8% of confirmed genetic diagnoses of FH satisfied clinical (Dutch lipid clinic network) criteria for a diagnosis. CONCLUSIONS: Our results emphasize the need for wider utilization of germline genetic sequencing for enhanced screening and detection of individuals who have familial hypercholesterolemia. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT05212428.


  • Response to: An International ASXL3 Natural History Study: Deep Phenotypic Analyses Including Detailed Reports of a Milder Phenotype, Novel Associations, and Clinical Recommendations

    by Shemonti Hasan, David Melville, Mohammad K. Chaaban, Ehab Y. Harahsheh, Bukola A. Olarewaju, Linnea M. Baudhuin, Wei Shen, Fadi Shamoun, Mayowa A. Osundiji

  • Open Access

    The Expanding Genetic Architecture of Arteriopathies: From Canonical TAAD Genes to Emerging Connective Tissue and Signaling Pathways

    by Luke Dreher, Hussein Abdul Nabi, Hunter Vandolah, Stephen Brennan, George Bcharah, Hend Bcharah, Mayowa A. Osundiji, Linnea M. Baudhuin, Fadi E. Shamoun

    Thoracic aortic aneurysm and dissection (TAAD) encompasses a clinically heterogeneous group of diseases characterized by high morbidity and mortality. Genetic studies over the past two decades have significantly expanded our understanding of the molecular landscape underlying heritable TAAD, revealing contributions from multiple interconnected biological pathways. This review systematically summarizes more than 75 genes implicated in TAAD pathogenesis, categorizing them according to major mechanistic roles including TGF-β signaling, extracellular matrix remodeling, smooth muscle cell contractility and cytoskeletal regulation, cell–matrix and cell–cell adhesion, metabolic processes, ion transport, and transcriptional regulation. Special emphasis is placed on emerging genes with variable or overlapping clinical phenotypes, dual-mechanism candidates, and their implications for personalized clinical management, including surveillance and surgical intervention thresholds. The integration of molecular insights into clinical practice, along with cautious consideration of genes of uncertain significance, promises to enhance diagnostic precision and risk stratification in individuals and families affected by heritable aortic disease.


  • Open Access

    Beyond the Echo: Is Comprehensive Vascular Exploration Valuable in Cases of Non-Syndromic Thoracic Aortic Aneurysms or Bicuspid Aortic Valve?

    by Austin Saugstad, Srekar Ravi, George Bcharah, Christine E. Firth, Hend Bcharah, Hussein Abdul Nabi, Hoang Nhat Pham, Ramzi Ibrahim, Sant J. Kumar, Mahmoud Abdelnabi, et al.

    Bicuspid aortic valve (BAV) and thoracic aortic aneurysms and dissections (TAAD) are recognized in syndromic connective tissue diseases (CTD), but most cases occur sporadically. The extent to which non-syndromic BAV or TAAD predisposes to additional arteriopathies, particularly in younger individuals, remains unclear. We retrospectively analyzed 1438 patients (mean age = 48.0, 67.7% female), excluding those with CTDs. Participants were ≤60 years old and categorized by the presence of BAV and/or TAAD. We examined co-existing arterial pathologies, including fibromuscular dysplasia, spontaneous coronary artery dissection, abdominal aortic aneurysms (AAA), mesenteric, peripheral extremity, and carotid/cerebral arteriopathies. Overall, 44.6% had either BAV or TAAD, and 27.2% had multiple arteriopathies. While vascular diseases were frequently noted, odds ratios demonstrated no significantly increased risk of extra-aortic arteriopathies in the BAV or TAAD cohorts. AAA exhibited a non-significant trend toward higher prevalence in TAAD patients. These findings support current guidelines recommending targeted imaging (transthoracic echocardiography of the aortic root and ascending aorta) over comprehensive “head-to-pelvis” screening for non-syndromic BAV or TAAD patients without additional risk factors. Ongoing genetic analyses may elucidate whether particular variants predispose to multi-site aneurysms or dissections. Consequently, targeted surveillance remains appropriate, with broader imaging reserved for patients with genetic or clinical indicators of higher risk.


  • Open Access

    Mosaic Copy Number Variation in a Patient with Cerebral and Pulmonary Arteriovenous Malformations and Recurrent Epistaxis

    by Sharri S Cyrus, Michelle L Kluge, Cherisse A Marcou, Erik C Thorland, Vivek N Iyer, Linnea M Baudhuin

    A 45-year-old female presented to internal medicine for evaluation and treatment of a cerebral arteriovenous malformation (AVM) with associated partial seizures. The patient reported her first seizure in the year prior to presentation and subsequent brain imaging confirmed the presence of an inferior right temporal cerebral AVM roughly 2.5 cm in diameter. She subsequently underwent definitive treatment of the AVM in a staged manner with initial partial coil embolization and stereotactic guided Gamma Knife radiosurgery performed 1 month later.